Abstract
In response to the demand for N95 respirators by healthcare workers during the COVID-19 pandemic, we evaluated decontamination of N95 respirators using an aerosolized hydrogen peroxide (aHP) system. This system is designed to dispense a consistent atomized spray of aerosolized, 7% hydrogen peroxide (H2O2) solution over a treatment cycle. Multiple N95 respirator models were subjected to ten or more cycles of respirator decontamination, with a select number periodically assessed for qualitative and quantitative fit testing. In parallel, we assessed the ability of aHP treatment to inactivate multiple viruses absorbed onto respirators, including phi6 bacteriophage, HSV-1, CVB3, and SARS-CoV-2. For pathogens transmitted via respiratory droplets and aerosols, it is critical to address respirator safety for reuse. This study provided experimental validation of an aHP treatment process that decontaminates the respirators while maintaining N95 function. External NIOSH certification verified respirator structural integrity and filtration efficiency after ten rounds of aHP treatment. Virus inactivation by aHP was comparable to the decontamination of commercial spore-based biological indicators. These data demonstrate that the aHP process is effective, with successful fit-testing of respirators after multiple aHP cycles, effective decontamination of multiple virus species including SARS-CoV- 2, successful decontamination of bacterial spores, and filtration efficiency maintained at or greater than 95%. While this study did not include extended or clinical use of N95 respirators between aHP cycles, these data provide proof of concept for aHP decontamination of N95 respirators before reuse in a crisis-capacity scenario.
Importance The COVID-19 pandemic led to unprecedented pressure on healthcare and research facilities to provide personal protective equipment. The respiratory nature of the SARS-CoV2 pathogen makes respirator facepieces a critical protection measure to limit inhalation of this virus. While respirator facepieces were designed for single-use and disposal, the pandemic increased overall demand for N95 respirators, and corresponding manufacturing and supply chain limitations necessitated the safe reuse of respirators when necessary. In this study, we repurposed an aerosolized hydrogen peroxide (aHP) system that is regularly utilized to decontaminate materials in a biosafety level 3 (BSL3) facility, to develop methods for decontamination of N95 respirators. Results from virus inactivation, biological indicators, respirator fit testing, and filtration efficiency testing all indicated that the process was effective at rendering N95 respirators safe for reuse. This proof-of-concept study establishes baseline data for future testing of aHP in crisis capacity respirator-reuse scenarios.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was a largely volunteer-based effort, with support from the Pennsylvania State University and The Penn State Institutes of Energy and the Environment. SARS-CoV-2 research in Dr. Troy Sutton's laboratory was initiated by a seed grant from The Huck Institutes of Life Sciences at Pennsylvania State University, and Dr. Sutton's research is further supported by the USDA National Institute of Food and Agriculture, Hatch project 4605.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵^ co-first-authors
Author emails: Mark A. Bates: mxb20{at}psu.edu, Matthew D. Beckman: mdb268{at}psu.edu, T. Hans Derr: thd12{at}psu.edu, Cassandra Field: cif5202{at}psu.edu, Kevin L. Hockett: klh450{at}psu.edu, Melissa A. James: maj22{at}psu.edu, Prem Kandel: kandelpremp{at}gmail.com, Chad V. Kuny: cvk108{at}psu.edu, Devanshi Patel: drp5323{at}psu.edu, Troy C. Sutton: tcs38{at}psu.edu, Moriah L. Szpara: moriah{at}psu.edu
Abbreviations: aHP, aerosolized hydrogen peroxide (H2O2); BSL, biosafety level; COVID-19, coronavirus disease 2019; CVB3, coxsackievirus B3; H2O2, hydrogen peroxide; HPM, hydrogen peroxide vapor monitor; HSV-1, herpes simplex virus 1; phi6, Pseudomonas phi6 bacteriophage; OSHA, Occupational Safety and Health Administration; QLFT, qualitative fit test; QNFT, quantitative fit-test; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VHP, Vapor-phase hydrogen peroxide.
This manuscript includes revisions to address recommendations from peer review.
Data Availability
All data is included in this publication. Supplemental Table 1 is available from the authors & included in the peer-review submission.
